Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Otsuka Beijing Research Institute

Home Clinical Trial Sponsors and OrganizationsOtsuka Beijing Research Institute

Otsuka Beijing Research Institute

ACTIVE

No.1, East Chang'an Street, Dongcheng District, 北京市, Chinawww.obri.com.cnSubsidiaryEstablished: 2003-08-29

Part of OTSUKA PHARMACEUTICAL CO., LTD.

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

36

2 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

2003

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

14

38.9%

Phase 3

12

33.3%

Phase 2

5

13.9%

Phase 4

4

11.1%

Not Applicable

1

2.8%

Trial Status Distribution

Active, not recruiting

2

5.6%

Completed

33

91.7%

Terminated

1

2.8%

Clinical Trials

Trials sponsored by this organization (36)

PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic Syndromes

Active, not recruiting

Oct 202372 participants

Phase II Clinical Trial of OPS-2071 in the Treatment of Irritable Bowel Syndrome of Diarrhea Type

Aug 202387 participants

To Demonstrate the Superiority of IMP (0.3% and 1% OPA-15406 Ointment) Versus the Vehicle in Pediatric Patients with AD

Feb 2023240 participants

To Demonstrate the Superiority of IMP (1% OPA-15406 Ointment) to the Vehicle in Adult Patients With AD

Feb 2023270 participants

Safety and Tolerability, and PK of Sibeprenlimab in Chinese Healthy Subject

Oct 202224 participants

OPC-1085EL in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Chinese Subjects

Sep 2022204 participants

OPC-61815 in Healthy Chinese Male Subjects

Jun 202218 participants

The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation

Active, not recruiting

Jul 202093 participants

Page 1 of 5

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials36
Approvals
News

Back to Organizations